MQ710
AXP000192.1 · Viral vector gene therapy
- Platform
- MVA (E5R-deleted)
- Originator
- Memorial Sloan Kettering Cancer Center
- Sponsor
- Memorial Sloan Kettering Cancer Center
Names
Virus
- Role
- In vivo gene transfer
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA (E5R-deleted)
- Replication
- non replicating
- Modifications
- E5R deleted; Flt3L and OX40L cassettes inserted
- Transgenes
- FLT3LG, TNFSF4
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C199613
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Recruiting | Phase 1 | 2023-05-04 | 2028-05-04 | 56 | Adnexal Carcinoma; Advanced Cancer; Angiosarcoma; BCC; BCC - Basal Cell Carcinoma; Basal Cell Carcinoma; Cutaneous Neoplasm; Cutaneous Squamous Cell Carcinoma; Extramammary Paget Disease; HNSCC; Head and Neck Squamous Cell Carcinoma; Kaposi Sarcoma; Melanoma; Merkel Cell Carcinoma; Metastatic Cancer; Refractory Cancer; SCC - Squamous Cell Carcinoma; Sebaceous Carcinoma; Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Notes
Non-replicating MVA with an E5R deletion expressing human Flt3L (FLT3LG) and OX40L (TNFSF4), injected intratumorally alone or with pembrolizumab; phase 1 NCT05859074. Recorded as in_vivo_gene_transfer rather than vaccine_vector because it delivers immune-stimulatory ligands, not a tumour antigen; it is not oncolytic (MVA does not replicate in human cells).
How to cite
MQ710 (AXP000192.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000192.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.